



(12) Translation of
European patent specification

(11) NO/EP 3239153 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 491/052 (2006.01)
A61K 31/4188 (2006.01)
A61P 31/14 (2006.01)

Norwegian Industrial Property Office






(21)	Translation Published	2019.09.02
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.05.08
(86)	European Application Nr.	17160683.3
(86)	European Filing Date	2013.05.15
(87)	The European Application's Publication Date	2017.11.01
(30)	Priority	2012.05.16, US, 201261647966 P 2013.03.14, US, 201313831116
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP2850085, 2013.05.15
(73)	Proprietor	Gilead Pharmasset LLC, 333 Lakeside Drive, Foster City, CA 94404, USA
(72)	Inventor	BACON, Elizabeth M., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA California 94404, USA COTTELL, Jeromy J., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA California 94404, USA LINK, John O., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA California 94404, USA TREJO MARTIN, Teresa Alejandra, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA California 94404, USA
(74)	Agent or Attorney	OSLO PATENTKONTOR AS, Postboks 7007 M, 0306 OSLO, Norge


(54)	Title	9-(1H-IMIDAZOL-5-YL)-1,11-DIHYDROISOCHROMENO[4',3':6,7]NAPHTHO[1,2-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HCV NS5A
(56)	References Cited:	WO-A1-2009/102633 WO-A2-2012/068234 WO-A1-2010/132601 WO-A1-2014/100500


Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>


Patentkrav


1. Forbindelse valgt fra:









































eller et farmasøytisk akseptabelt salt derav.


2. Forbindelse ifølge krav 1 valgt fra:









































3. Forbindelse eller farmasøytisk akseptabelt salt ifølge krav 1, for anvendelse i profylaktisk eller terapeutisk behandling av hepatitt C.

4. Forbindelse ifølge krav 2, for anvendelse i profylaktisk eller terapeutisk behandling av hepatitt C.

5. Farmasøytisk sammensetning omfattende forbindelse eller farmasøytisk akseptabelt salt ifølge krav 1 og minst en farmasøytisk akseptabel bærer.
6. Farmasøytisk sammensetning omfattende forbindelse ifølge krav 2 og minst en farmasøytisk akseptabel bærer.
7. Farmasøytisk sammensetning ifølge krav 5 eller krav 6, formulert for oral administrering.
8. Farmasøytisk sammensetning ifølge krav 5 eller krav 6, formulert i tablettform.
9. Farmasøytisk sammensetning ifølge krav 5 eller krav 6 for anvendelse i profylaktisk eller terapeutisk behandling av hepatitt C.